The Latest Breaking News from AbbVie

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

In today's volatile market, dividend stocks remain one of the safest choices.